G
gam197
Guest
FULL ARTICLE…
The Associated Press
WASHINGTON
The Federal Trade Commission said Friday that it has issued a formal approval of Barr Pharmaceuticals Inc.'s $2.5 billion acquisition of generic pharmaceutical company PLIVA d.d.
The FTC initially approved the transaction Oct. 20, subject to the sale of four product lines by Barr and PLIVA, which is based in Zagreb, Croatia. The initial approval was then followed by a 30-day public comment period, the agency said, and the FTC’s five commissioners then voted to formally approve the terms of the acquisition.
The Barr-Pliva combination creates the third-largest generic pharmaceutical company by revenue. The combined company will have a presence in over 30 countries, employ approximately 8,000 people and have annual revenue of about US$2.4 billion.
Shares of Barr Pharmaceuticals dropped 30 cents to end at $50.88 on the New York Stock Exchange.
businessweek.com/ap/financialnews/D8LSUNR80.htm
The Associated Press
WASHINGTON
The Federal Trade Commission said Friday that it has issued a formal approval of Barr Pharmaceuticals Inc.'s $2.5 billion acquisition of generic pharmaceutical company PLIVA d.d.
The FTC initially approved the transaction Oct. 20, subject to the sale of four product lines by Barr and PLIVA, which is based in Zagreb, Croatia. The initial approval was then followed by a 30-day public comment period, the agency said, and the FTC’s five commissioners then voted to formally approve the terms of the acquisition.
The Barr-Pliva combination creates the third-largest generic pharmaceutical company by revenue. The combined company will have a presence in over 30 countries, employ approximately 8,000 people and have annual revenue of about US$2.4 billion.
Shares of Barr Pharmaceuticals dropped 30 cents to end at $50.88 on the New York Stock Exchange.
businessweek.com/ap/financialnews/D8LSUNR80.htm